Top News

This cholesterol pellet can fight the high risk of heart attack and stroke: study

Sandy Verma | May 11, 2025 3:24 AM CST

An international team of mentors Found that cholesterol -reducing drug may be a more effective and convenient way to protect people with high risk of heart attack and stroke.

In Australia, a study conducted under the leadership of researchers at the University of Mashtra was tested once a daily oral drug called Obisatrape and found that LDL or poor cholesterol and lipoprotein (A), [एलपी (ए)] – Two major contributors of heart disease – both reduced both.

Director of the Victorian Heart Institute, University of the University, Professor Stephen Nicholes, Professor of the study said that the findings are an important step for patients who are struggling to reach their cholesterol target with current treatments.

Nicholas said, “We know that many people with high risk of heart attack or stroke are not able to reduce their cholesterol levels enough, even with the best available treatments.” Also read – Hidden threats of excessive intake of red meat

“Obissatrape provides a promising new option-it not only reduced LDL cholesterol more than 30 percent, but we also saw a decrease in LP (A), which is very difficult to treat and which has been linked to the risk of heart disease,” he said. LDL cholesterol, often called “poor cholesterol”, accumulates in blood vessels, and increases the risk of heart.

Lipoprotein (A), or LP (A), a less known but inherited risk factor that can also accelerate arterial damage – and unlike LDL, currently there is no widely accepted treatment to reduce it.

The trial published in the New England Journal of Medicine included more than 2,500 participants with heart disease or genetic high cholesterol, which were given either obsate or placebo, in addition to their regular cholesterol drugs. Also read – High blood pressure risk can be estimated after many years from blood pressure pattern in early pregnancy.

After 12 weeks, LDL cholesterol declined by 32.6 percent and LP (A) on an average of 33.5 percent – many people achieved guidelines for the first time. Obicrapibs were well tolerated, and security profiles were similar to the tests of the heart. Is.” “It is convenient, it is effective, and it can help reduce the difference for patients who do not have options.”